Description
PT-141 (bremelanotide) is FDA-approved for low sexual desire in premenopausal women. This guide covers how it works, dosage, side effects, and how to get it through telehealth, without insurance.
PT-141 for Women: What It Is, How It Works, and How to Get It
Table of Contents
- What Is PT-141?
- How Does PT-141 Work in Women?
- Who Is PT-141 For?
- PT-141 Dosage for Women
- What to Expect: Timeline and Results
- PT-141 Side Effects
- How to Get PT-141 Without Insurance
- Why Profusions?
#TLDR
PT-141 (bremelanotide) is FDA-approved for premenopausal women with hypoactive sexual desire disorder (HSDD). It works through brain-based arousal pathways, not blood flow, making it the only prescription option that targets desire at its neurological root. It's available via telehealth, no office visit required.
What Is PT-141?
PT-141, generic name bremelanotide, is a synthetic peptide that the FDA approved in 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Mayo Clinic
HSDD is characterized by a persistent, distressing absence of sexual thoughts, fantasies, or desire, not explained by relationship problems, another medical condition, or a medication side effect. It's more common than most people realize, yet it remains underdiagnosed and undertreated.
What sets PT-141 apart from other sexual health treatments is its mechanism. Instead of increasing blood flow like sildenafil or tadalafil, PT-141 activates melanocortin receptors in the brain, specifically the pathways involved in sexual arousal and motivation. The result is an increase in desire that originates centrally, from the nervous system itself.
How Does PT-141 Work in Women?
PT-141 is a melanocortin receptor agonist. When injected subcutaneously, it binds to melanocortin receptors (MC3R and MC4R) in the central nervous system, activating neural circuits associated with sexual motivation and arousal. PMC, Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women
This is a fundamentally different approach from PDE5 inhibitors like tadalafil, which work peripherally by relaxing smooth muscle in blood vessels. PT-141 doesn't rely on sexual stimulation already being present, it initiates the desire response at the brain level.
Two Phase 3 clinical trials (the RECONNECT trials) enrolled 1,267 premenopausal women with HSDD and demonstrated statistically significant improvements in sexually satisfying events and reductions in distress related to low sexual desire compared to placebo. PMC, Bremelanotide for Treatment of Female Hypoactive Sexual Desire
Who Is PT-141 For?
PT-141 is appropriate for premenopausal women who:
- Experience persistent low sexual desire that causes personal distress
- Have been diagnosed with or suspect HSDD
- Have not responded adequately to lifestyle changes or other treatments
- Are not pregnant or planning to become pregnant
- Do not have uncontrolled high blood pressure or cardiovascular disease
Women going through perimenopause or those on hormonal birth control who notice a significant drop in libido are among the most common candidates. PT-141 is also used off-label in postmenopausal women under clinician guidance, though the FDA approval specifically covers premenopausal patients.
PT-141 Dosage for Women
The FDA-approved dosage for bremelanotide (Vyleesi) is 1.75 mg, administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. Mayo Clinic
Key dosing rules:
- Do not use more than once in 24 hours
- Limit use to approximately 8 times per month based on clinical guidance
- Injection sites: abdomen or thigh
- Effects begin within 45 minutes and can last several hours
Through compounding pharmacies, some clinicians prescribe lower starting doses (0.5 mg–1.0 mg) to reduce the risk of nausea while the body acclimates. Your Profusions clinician will determine the appropriate starting dose based on your health history.
What to Expect: Timeline and Results
PT-141 works on an as-needed basis, not as a daily hormone replacement. Here's a realistic timeline:
First use: You may notice increased arousal or sexual interest within 45-60 minutes. Some women experience a milder response on the first dose as the body adjusts.
Weeks 2-4: With consistent use (as needed), most women report a more consistent and reliable response. Nausea, if it appeared initially, tends to lessen with repeated use.
Ongoing: Unlike traditional ED medications, the effect is on desire and motivation, not simply physical response. Many women describe it as restoring a sense of interest they had lost, rather than creating an artificial feeling.
Results vary. PT-141 has been shown in clinical trials to increase sexually satisfying events and reduce distress, but individual response depends on hormone levels, underlying health, and consistent use under medical supervision.
PT-141 Side Effects
The most common side effect is nausea, reported in a significant portion of clinical trial participants. It's typically mild to moderate and short-lived, usually resolving within a few hours of injection.
Other side effects documented in clinical trials include:
- Flushing (warmth or redness of the face and neck)
- Headache
- Transient blood pressure changes, blood pressure may decrease temporarily after injection, then increase
- Hyperpigmentation, with prolonged use, darkening of the face, gums, or breasts has been observed in a small percentage of users
Managing nausea: Injecting PT-141 at the thigh (rather than abdomen) and lying down for 30-60 minutes post-injection can reduce nausea intensity. Your clinician may also recommend an anti-nausea medication for the first few uses.
PT-141 should not be used if you have a history of cardiovascular disease, uncontrolled hypertension, or if you are pregnant. Mayo Clinic
How to Get PT-141 Without Insurance
Brand-name Vyleesi (bremelanotide 1.75 mg auto-injector) carries a retail cost that places it out of reach for many patients without insurance coverage. Compounded bremelanotide, prescribed through a licensed telehealth provider and dispensed by an FDA-registered compounding pharmacy, offers access at a substantially lower cost, and without requiring a physical office visit.
Through Profusions Health & Wellness:
- Complete an online intake form, no office visit required
- A licensed clinician reviews your health history and determines if PT-141 is appropriate
- If prescribed, your medication ships directly from one of our LegitScript-certified, US-licensed compounding pharmacy partners
- Ongoing clinician support is available throughout your treatment
This model removes the two biggest barriers to accessing sexual wellness care: cost and the discomfort of an in-person conversation.
Why Profusions?
Profusions Health & Wellness is a virtual clinic licensed across all 50 states. Our clinicians specialize in peptide therapy, hormone health, and sexual wellness, and our compounding pharmacy partners (Olympia, Strive, Emerald, Striker) maintain LegitScript certification and FDA registration.
Whether you're dealing with HSDD, hormonal shifts from perimenopause, or simply a loss of desire you can't explain, our team provides a private, clinical, evidence-based path forward.
Start your free evaluation at Profusions →
This article is for informational purposes only and does not constitute medical advice. Consult a licensed clinician before starting any prescription therapy.
